|
SESSIONS INCLUDE
-
DRIVERS,
CHALLENGES AND IMPLEMENTATION
-
IMPACT
OF BIOMARKERS AND MOLECULAR PROFILING ON DISCOVERY
-
AND
DEVELOPMENT
-
CHOOSING
AN IMAGING MODALITY FOR BOTH INTERNAL DECISION
-
MAKING
AND REGULATORY APPROVAL
-
TRANSLATIONAL
ONCOLOGY
-
PHARMACEUTICAL
EXPLORATION
PLENARY
KEYNOTE SPEAKERS
Diagnosing
the Disease: Disruptive Innovation
in Healthcare
Clayton M. Christensen, DBA, Robert and Jane Cizik
Professor of Business Administration, Harvard Business
School
Disruption
of the Pharmaceutical Industry:
Moving from Products to Solutions
 Elizabeth
L. Bewley, MBA, Vice President, Strategic Planning, Johnson &
Johnson Health Care Systems Inc.
Risk
Diagnosis for Disease Prevention
C. Thomas Caskey, M.D., F.A.C.P., Director and Chief
Executive Officer, Brown Foundation Institute of
Molecular Medicine, University of Texas Health Science
Center
PANELS AND BREAKOUT DISCUSSIONS
-
Panel Discussion: What Does It Take to Qualify a Biomarker as a Surrogate
Endpoint?
-
Breakout Discussion 1: Translational Science Across the Globe: Needs, Opportunities and
Challenges
-
Breakout Discussion 2: Use of Biomarkers to Make Go / No-go Decisions ・Are We
Ready?
-
Breakout Discussion 3: How Translational Medicine Can Contribute to Early R&D Productivity Using a Standards of Evidence Approach
|
Japanese
Korean
English